Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

Corey Good­man has put an­oth­er notch on his ven­ture belt, ring­ing up a $105 mil­lion mega-round for his CD47 start­up ALX On­col­o­gy.

Fu­el­ing a start­up backed by his group at ven­BIO, the new mon­ey will go to a slate of mid-stage stud­ies to test the the­o­ry that his biotech’s ALX 148 could be a game-chang­er in the CD47 are­na. And that could be nice win­dow dress­ing for a com­pa­ny that may be look­ing to go the IPO route.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN